Meeting
2023 ASCO Annual Meeting
A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1) and early-stage NSC lung cancer detection.
Authors
Janneta Tcherkassova
UCM Technologies Inc., Toronto, ON, Canada
Janneta Tcherkassova , Sergei Tsurkan , Anna Prostyakova , Evgueni Klinski , Marina Sekacheva , Alexander Boroda , Ricardo Moro , David Berz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3038)
DOI
10.1200/JCO.2023.41.16_suppl.3038
Abstract #
3038
Poster Bd #
236
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
A novel artificial intelligence-enhanced electrochemical method for rapid methylation detection in cfDNA: Advancing multi-cancer early diagnosis.
First Author: Li-Yue Sun
Poster
2023 ASCO Annual Meeting
A panel of seven protein tumor markers for multi-cancer early detection by artificial intelligence.
First Author: Shichun Tu
Poster
2021 ASCO Annual Meeting
The prognostic value of tumor markers in patients (pts) with resectable gastric cancer (GC) receiving perioperative therapy in the CRITICS trial.
First Author: Astrid E. Slagter
Poster
2019 Gastrointestinal Cancers Symposium
Predicting imminent disease progression in advanced colorectal cancer by a machine-learning algorithm.
First Author: Yuri Kogan